Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 11/20 | 0.43 |
| ▸ | GSK3B | P49841 | 6/20 | 0.43 |
| ▸ | CDK1 | P06493 | 6/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.43 |
| ▸ | CDC7 | O00311 | 4/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.43 |
| ▸ | PRKACA | P17612 | 4/20 | 0.43 |
| ▸ | HIPK2 | Q9H2X6 | 4/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | PIM1 | P11309 | 3/20 | 0.43 |
| ▸ | FLT3 | P36888 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.43 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.43 |
| ▸ | INSR | P06213 | 2/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13638552 | 0.89 | RET (0.40) | RETGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL4501971 | 0.88 | CDK7 (0.39) | RETGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL4481423 | 0.86 | RET (0.42) | RETGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL3477635 | 0.85 | CDK2 (0.51) | RETGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL4498249 | 0.85 | GSK3B (0.56) | RETGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL3472900 | 0.83 | EGFR (0.43) | RETGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL4485127 | 0.82 | RET (0.51) | RETGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL3477612 | 0.82 | RET (0.50) | RETGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL4490390 | 0.82 | MAPK8 (0.41) | RETGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL4493639 | 0.82 | RET (0.49) | RETGSK3BCDK1CCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615898-B1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | claimed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | claimed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | claimed |
| EP-1615898-B1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| EP-1615898-B1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| CN-102267988-A | 2-aminopyrimidine derivatives and their medical use | NOVARTIS LTD | 2011-12-07 | — | — | CN | disclosed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| CN-1802357-A | 2-aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2006-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | RET 3044/4885GSK3B 906/4885CDK1 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.